Literature DB >> 22268274

Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women.

G Mainini1, M Incoronato, L Urso, C Scaffa.   

Abstract

PURPOSE OF INVESTIGATION: Osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) are bone turnover modulators expressed by osteoblasts. The aim of this study was to assess the relationship between the circulating OPG/RANKL system, age and bone mass, in fertile age and postmenopausal women.
METHODS: In this cross-sectional observational study on 48 patients (fertile age, n = 22; postmenopause, n = 26), we investigated the correlation between serum OPG and RANKL, age and bone mineral density (BMD). Serum concentrations of OPG and RANKL were determined by enzyme-linked immunosorbent assay (ELISA); estimate BMD evaluation was performed with heel quantitative ultrasonometry (QUS).
RESULTS: Serum OPG significantly increased (p = 0.003) and serum RANKL significantly decreased (p = 0.002), in the postmenopausal group compared to fertile age women. A significant correlation of serum OPG with age (r(s) = 0.39, p = 0.047) and BMD (r(s) = 0.45, p = 0.023) in postmenopausal women, and between RANKL and BMD (r(s) = 0.48, p = 0.024) in fertile age was found.
CONCLUSION: These data demonstrate in vivo that the OPG/RANKL system is significantly associated with menopausal status and could play a role in postmenopausal osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22268274

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  4 in total

1.  Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis.

Authors:  Abdul M Tyagi; Kamini Srivastava; Mohd Nizam Mansoori; Ritu Trivedi; Naibedya Chattopadhyay; Divya Singh
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

Review 2.  Osteoporosis: the current status of mesenchymal stem cell-based therapy.

Authors:  Jitrada Phetfong; Tanwarat Sanvoranart; Kuneerat Nartprayut; Natakarn Nimsanor; Kanokwan Seenprachawong; Virapong Prachayasittikul; Aungkura Supokawej
Journal:  Cell Mol Biol Lett       Date:  2016-08-12       Impact factor: 5.787

3.  Bone Alterations in Inflammatory Bowel Diseases: Role of Osteoprotegerin.

Authors:  Kateryna Priadko; Antimo Moretti; Giovanni Iolascon; Antonietta Gerarda Gravina; Agnese Miranda; Dolores Sgambato; Cristiana De Musis; Marco Romano; Francesca Gimigliano
Journal:  J Clin Med       Date:  2022-03-26       Impact factor: 4.241

4.  Serum Osteoprotegerin Is an Independent Marker of Left Ventricular Hypertrophy, Systolic and Diastolic Dysfunction of the Left Ventricle and the Presence of Pericardial Fluid in Chronic Kidney Disease Patients.

Authors:  Katarzyna Romejko; Aleksandra Rymarz; Katarzyna Szamotulska; Zbigniew Bartoszewicz; Stanisław Niemczyk
Journal:  Nutrients       Date:  2022-07-14       Impact factor: 6.706

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.